Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical TrialAnirban P. Mitra, Colin P. Dinney, Vikram M. Narayan et al.|European Urology|2021Cited by 24
Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approvalAlberto Martini, Colin P. Dinney, Côme Tholomier et al.|Frontiers in Immunology|2023Cited by 24
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer Treated with Nadofaragene FiradenovecVikram M. Narayan, Colin P. Dinney, Côme Tholomier et al.|European Urology Oncology|2024Cited by 18
The current status of gene therapy in bladder cancerCôme Tholomier, Colin P. Dinney, Alberto Martini et al.|Expert Review of Anticancer Therapy|2023Cited by 14
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder CancerSharada Mokkapati, Colin P. Dinney, Sima P. Porten et al.|Molecular Cancer Research|2020Cited by 12